Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment
Olga Mitelman, Hoda Abdel‐Hamid, Barry J. Byrne, et al.
Journal of Neuromuscular Diseases (2021) Vol. 9, Iss. 1, pp. 39-52
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Amplifying gene expression with RNA-targeted therapeutics
Olga Khorkova, Jack Stahl, Aswathy Joji, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 539-561
Open Access | Times Cited: 70
Duchenne muscular dystrophy: pathogenesis and promising therapies
Mengyuan Chang, Yong Cai, Zihui Gao, et al.
Journal of Neurology (2023) Vol. 270, Iss. 8, pp. 3733-3749
Closed Access | Times Cited: 27
Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping
Eugenio Mercuri, A. Seferian, Laurent Servais, et al.
Neuromuscular Disorders (2023) Vol. 33, Iss. 6, pp. 476-483
Closed Access | Times Cited: 19
Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis
Erik Landfeldt, Alicia Alemán, Sophia Abner, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 3, pp. 579-612
Open Access | Times Cited: 7
Gene therapy for ultrarare diseases: a geneticist’s perspective
Wuh‐Liang Hwu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 7
Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges
David J. Birnkrant, Luca Bello, Russell J. Butterfield, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 4, pp. 403-420
Open Access | Times Cited: 26
Breathing in Duchenne muscular dystrophy: translation to therapy
Doreen Mhandire, David P. Burns, Angela L. Roger, et al.
The Journal of Physiology (2022) Vol. 600, Iss. 15, pp. 3465-3482
Open Access | Times Cited: 24
Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy
Eleonora S. D’Ambrosio, Jerry R. Mendell
Neurotherapeutics (2023) Vol. 20, Iss. 6, pp. 1669-1681
Open Access | Times Cited: 11
Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls
Joel Iff, Nicolae Done, Edward Tuttle, et al.
Muscle & Nerve (2024) Vol. 70, Iss. 1, pp. 60-70
Open Access | Times Cited: 4
Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
Anne M. Connolly, Craig M. Zaidman, John F. Brandsema, et al.
Journal of Neuromuscular Diseases (2023) Vol. 10, Iss. 4, pp. 685-699
Open Access | Times Cited: 10
A historical perspective on the development of antisense oligonucleotide treatments for Duchenne muscular dystrophy and spinal muscular atrophy
Annemieke Aartsma‐Rus, Shin’ichi Takeda
Journal of Neuromuscular Diseases (2025)
Closed Access
Valproic Acid Improves Antisense-Mediated Exon-Skipping Efficacy in mdx Mice
Micky Phongsavanh, Flavien Bizot, Amel Saoudi, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2583-2583
Open Access
Natural antisense transcripts as drug targets
Olga Khorkova, Jack Stahl, Aswathy Joji, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 15
Dimethyl fumarate modulates the dystrophic disease program following short-term treatment
Cara A. Timpani, Stephanie Kourakis, Danielle Debruin, et al.
JCI Insight (2023) Vol. 8, Iss. 21
Open Access | Times Cited: 9
Therapeutic targeting of RNA for neurological and neuromuscular disease
Jodi L. Bubenik, Marina M. Scotti, Maurice S. Swanson
Genes & Development (2024)
Open Access | Times Cited: 3
A qualitative study to understand the Duchenne muscular dystrophy experience from the parent/patient perspective
Victoria Brown, Elizabeth Merikle, Kelly L. Johnston, et al.
Journal of Patient-Reported Outcomes (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 8
The Early Care (0–3 Years) In Duchenne Muscular Dystrophy Meeting Report
Niki Armstrong, Susan Apkon, Kiera N. Berggren, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 2, pp. 525-533
Open Access | Times Cited: 2
Eteplirsen Treatment for Duchenne Muscular Dystrophy: A Qualitative Patient Experience Study
Joel Iff, Chloe Carmichael, Stephanie McKee, et al.
Advances in Therapy (2024) Vol. 41, Iss. 8, pp. 3278-3298
Open Access | Times Cited: 2
Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice
Flavien Bizot, Remko Goossens, Thomas Tensorer, et al.
Molecular Therapy — Nucleic Acids (2022) Vol. 30, pp. 606-620
Open Access | Times Cited: 8
Empowerment of genetic information by women at-risk of being carriers of Duchenne and Becker muscular dystrophies
Alice Maria Luderitz Hoefel, Cesar Augusto Weschenfelder, Bruna Faria Rosa, et al.
Journal of Community Genetics (2024) Vol. 15, Iss. 2, pp. 163-175
Open Access | Times Cited: 1
Brothers with Becker muscular dystrophy show discordance in skeletal muscle computed tomography findings: A case report
Yoshinori Nambu, Taku Shirakawa, Kayo Osawa, et al.
SAGE Open Medical Case Reports (2024) Vol. 12
Open Access | Times Cited: 1
Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States
Alexa C. Klimchak, Lauren E. Sedita, Louise R. Rodino‐Klapac, et al.
Journal of Market Access & Health Policy (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 3
Gene therapy review: Duchenne muscular dystrophy case study
Édouard Berling, Romain Nicolle, Pascal Laforêt, et al.
Revue Neurologique (2022) Vol. 179, Iss. 1-2, pp. 90-105
Open Access | Times Cited: 5
Methodology of a Natural History Study of a Rare Neurodevelopmental Disorder: Alternating Hemiplegia of Childhood as a Prototype Disease
Shital Patel, Eleni Panagiotakaki, Maria Papadopoulou, et al.
Journal of Child Neurology (2023) Vol. 38, Iss. 10-12, pp. 597-610
Open Access | Times Cited: 2
Sleep in pediatric neuromuscular disorders
John E. Pascoe, A. Zygmunt, Zarmina Ehsan, et al.
Seminars in Pediatric Neurology (2023) Vol. 48, pp. 101092-101092
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top